Cargando…
Cyclin-Dependent Kinase Subunit 2 (CKS2) as a Prognostic Marker for Stages I–III Invasive Non-Mucinous Lung Adenocarcinoma and Its Role in Affecting Drug Sensitivity
With the aim of improving the prognosis of patients with lung adenocarcinoma (LUAD), we identified the biomarker related to the sensitivity of patients to chemotherapy drugs and explored the potential mechanisms. As a cell cycle-related protein, CKS2 has an essential role to play in tumor progressio...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406629/ https://www.ncbi.nlm.nih.gov/pubmed/36010686 http://dx.doi.org/10.3390/cells11162611 |
_version_ | 1784774167526113280 |
---|---|
author | Feng, Junkai Hu, Menglong Li, Zongkuo Hu, Guiming Han, Yuting Zhang, Yan Zhang, Min Ren, Jingli |
author_facet | Feng, Junkai Hu, Menglong Li, Zongkuo Hu, Guiming Han, Yuting Zhang, Yan Zhang, Min Ren, Jingli |
author_sort | Feng, Junkai |
collection | PubMed |
description | With the aim of improving the prognosis of patients with lung adenocarcinoma (LUAD), we identified the biomarker related to the sensitivity of patients to chemotherapy drugs and explored the potential mechanisms. As a cell cycle-related protein, CKS2 has an essential role to play in tumor progression and prognosis. CKS2 expression was measured using TCGA RNA-sequencing data and immunohistochemistry. The sensitivity data of tumor cells to chemotherapeutic drugs for lung cancer was acquired from the Cancer Therapeutics Response Portal (CTRP) database. A range of bioinformatics methods was used to explore the mechanisms of CKS2 upregulation. The biological functions of CKS2 were predicted using GO and KEGG enrichment analysis, as well as GSEA. CKS2 expression was up-regulated in stages I–III invasive non-mucinous lung adenocarcinoma and varied significantly between various histological subtypes. High CKS2 expression worsened the prognosis of patients. The CKS2 expression level was linked to the sensitivity of LUAD cells to carboplatin and paclitaxel. CKS2 upregulation was associated with the immune microenvironment, mRNA methylation, and competing endogenous RNAs (ceRNAs). CKS2 can serve as a diagnostic and prognostic biomarker for stages I–III invasive non-mucinous lung adenocarcinoma and modulate the effect of paclitaxel and carboplatin by regulating microtubule binding and influencing carboplatin binding to DNA. |
format | Online Article Text |
id | pubmed-9406629 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94066292022-08-26 Cyclin-Dependent Kinase Subunit 2 (CKS2) as a Prognostic Marker for Stages I–III Invasive Non-Mucinous Lung Adenocarcinoma and Its Role in Affecting Drug Sensitivity Feng, Junkai Hu, Menglong Li, Zongkuo Hu, Guiming Han, Yuting Zhang, Yan Zhang, Min Ren, Jingli Cells Article With the aim of improving the prognosis of patients with lung adenocarcinoma (LUAD), we identified the biomarker related to the sensitivity of patients to chemotherapy drugs and explored the potential mechanisms. As a cell cycle-related protein, CKS2 has an essential role to play in tumor progression and prognosis. CKS2 expression was measured using TCGA RNA-sequencing data and immunohistochemistry. The sensitivity data of tumor cells to chemotherapeutic drugs for lung cancer was acquired from the Cancer Therapeutics Response Portal (CTRP) database. A range of bioinformatics methods was used to explore the mechanisms of CKS2 upregulation. The biological functions of CKS2 were predicted using GO and KEGG enrichment analysis, as well as GSEA. CKS2 expression was up-regulated in stages I–III invasive non-mucinous lung adenocarcinoma and varied significantly between various histological subtypes. High CKS2 expression worsened the prognosis of patients. The CKS2 expression level was linked to the sensitivity of LUAD cells to carboplatin and paclitaxel. CKS2 upregulation was associated with the immune microenvironment, mRNA methylation, and competing endogenous RNAs (ceRNAs). CKS2 can serve as a diagnostic and prognostic biomarker for stages I–III invasive non-mucinous lung adenocarcinoma and modulate the effect of paclitaxel and carboplatin by regulating microtubule binding and influencing carboplatin binding to DNA. MDPI 2022-08-22 /pmc/articles/PMC9406629/ /pubmed/36010686 http://dx.doi.org/10.3390/cells11162611 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Feng, Junkai Hu, Menglong Li, Zongkuo Hu, Guiming Han, Yuting Zhang, Yan Zhang, Min Ren, Jingli Cyclin-Dependent Kinase Subunit 2 (CKS2) as a Prognostic Marker for Stages I–III Invasive Non-Mucinous Lung Adenocarcinoma and Its Role in Affecting Drug Sensitivity |
title | Cyclin-Dependent Kinase Subunit 2 (CKS2) as a Prognostic Marker for Stages I–III Invasive Non-Mucinous Lung Adenocarcinoma and Its Role in Affecting Drug Sensitivity |
title_full | Cyclin-Dependent Kinase Subunit 2 (CKS2) as a Prognostic Marker for Stages I–III Invasive Non-Mucinous Lung Adenocarcinoma and Its Role in Affecting Drug Sensitivity |
title_fullStr | Cyclin-Dependent Kinase Subunit 2 (CKS2) as a Prognostic Marker for Stages I–III Invasive Non-Mucinous Lung Adenocarcinoma and Its Role in Affecting Drug Sensitivity |
title_full_unstemmed | Cyclin-Dependent Kinase Subunit 2 (CKS2) as a Prognostic Marker for Stages I–III Invasive Non-Mucinous Lung Adenocarcinoma and Its Role in Affecting Drug Sensitivity |
title_short | Cyclin-Dependent Kinase Subunit 2 (CKS2) as a Prognostic Marker for Stages I–III Invasive Non-Mucinous Lung Adenocarcinoma and Its Role in Affecting Drug Sensitivity |
title_sort | cyclin-dependent kinase subunit 2 (cks2) as a prognostic marker for stages i–iii invasive non-mucinous lung adenocarcinoma and its role in affecting drug sensitivity |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406629/ https://www.ncbi.nlm.nih.gov/pubmed/36010686 http://dx.doi.org/10.3390/cells11162611 |
work_keys_str_mv | AT fengjunkai cyclindependentkinasesubunit2cks2asaprognosticmarkerforstagesiiiiinvasivenonmucinouslungadenocarcinomaanditsroleinaffectingdrugsensitivity AT humenglong cyclindependentkinasesubunit2cks2asaprognosticmarkerforstagesiiiiinvasivenonmucinouslungadenocarcinomaanditsroleinaffectingdrugsensitivity AT lizongkuo cyclindependentkinasesubunit2cks2asaprognosticmarkerforstagesiiiiinvasivenonmucinouslungadenocarcinomaanditsroleinaffectingdrugsensitivity AT huguiming cyclindependentkinasesubunit2cks2asaprognosticmarkerforstagesiiiiinvasivenonmucinouslungadenocarcinomaanditsroleinaffectingdrugsensitivity AT hanyuting cyclindependentkinasesubunit2cks2asaprognosticmarkerforstagesiiiiinvasivenonmucinouslungadenocarcinomaanditsroleinaffectingdrugsensitivity AT zhangyan cyclindependentkinasesubunit2cks2asaprognosticmarkerforstagesiiiiinvasivenonmucinouslungadenocarcinomaanditsroleinaffectingdrugsensitivity AT zhangmin cyclindependentkinasesubunit2cks2asaprognosticmarkerforstagesiiiiinvasivenonmucinouslungadenocarcinomaanditsroleinaffectingdrugsensitivity AT renjingli cyclindependentkinasesubunit2cks2asaprognosticmarkerforstagesiiiiinvasivenonmucinouslungadenocarcinomaanditsroleinaffectingdrugsensitivity |